ABSTRACT

Antibiotic management of infectious exacerbations of chronic obstructive pulmonary disease

Chronic obstructive pulmonary disease (COPD) is one of the most important and common disorders due to its progressive nature and high incidence of exacerbations. An acute exacerbation of COPD refers to sustained worsening of symptoms in a previously stable patient. Exacerbations (including severe exacerbations) are often due to causes other than bacterial infections and as such they are non-responsive to antibiotics. The NICE guidelines provide an antimicrobial prescribing strategy for acute exacerbations of COPD with the aim of optimizing antibiotic use and reducing antibiotic resistance in affected patients. Antibiotics which are typically indicated for bacterial exacerbations can also speed up the recovery as well as reduce the risk of early relapse and treatment failure.

Piśmiennictwo

1. Pauwels R, Calverley P, Buist AS, et al. COPD exacerbations: the importance of a standard definition. Respir Med 2004;98:99-107

2. Caramori G, Adcock IM, Papi A. Clinical definition of COPD exacerbations and classification of their severity. South Med J 2009;102:277-82

3. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363:1128-38

4. Suissa S, Dell’Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax 2012;67(11):957-63

5. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2018. http://goldcopd. org (dostęp: 20.04.2018)

6. Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing (NG114), NICE guideline. Published: 5 December 2018, nice.org.uk/guidance/ng114. NICE 2018

7. Blasi F, Legnani D, Lombardo VM, et al. Chlamydia pneumoniae infection in acute exacerbations of COPD. Eur Respir J 1993;6:19-22

8. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204

9. Sethi S, Wrona C, Eschberger K, et al. Inflammatory profile of new bacterial strain exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;177:491-7

10. Central Asian and Eastern European Surveillance of Antimicrobial Resistance. Annual report 2018, World Health Organization 2018, http://www.euro.who.int/en/health-topics/disease-prevention/antimicrobial resistance/publications

11. Drug allergy: diagnosis and management. National Institute for Health and Care Excellence Clinical guideline Published: 3 September 2014. nice.org.uk/guidance/cg183.

12. Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics. EMEA 2018.11.16 (dostęp:17.12.2018)

13. Vollenweider DJ, Jarrett H, Steurer-Stey CA, et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012 Dec 12;12:CD010257. doi: 10.1002/14651858.CD010257

14. Stolbrink M, Amiry J, Blakey JD. Does antibiotic treatment duration affect the outcomes of exacerbations of asthma and COPD? A systematic review. Chron Respir Dis 2018;15(3):225-40. doi: 10.1177/1479972317745734

15. Falagas M, Avgeri S, Matthaiou Det al. Short- versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis: a meta-analysis. J Antimicrob Chemother 2008;62:442-50

16. Hryniewicz W, Albrecht P, Radzikowski A (red.). Rekomendacje postępowania w pozaszpitalnych zakażeniach układu oddechowego. Warszawa: Narodowy Instytut Leków, 2016

Do góry